A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.

ABSTRACT:

Background

The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is generally attributable to metastatic disease undetected at complete resection. Management of such patients depends on prognostic staging to identify the individuals most likely to have occult disease. We aimed to develop and validate a practical, reliable assay that improves risk stratification compared with conventional staging.

Methods

A 14-gene expression assay that uses quantitative PCR, runs on formalin-fixed paraffin-embedded tissue samples, and differentiates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with non-squamous NSCLC resected at the University of California, San Francisco. The assay was then independently validated by the Kai

SUBMITTER: Kratz JR 

PROVIDER: S-EPMC3294002 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature